SystImmune and Bristol Myers Squibb announce interim Phase III data showing Iza-bren significantly improves outcomes in previously treated triple-negative breast cancer (TNBC) patients. SystImmune, Inc. and Bristol Myers Squibb have announced positive topline results from a pivotal Phase III clinical…
Evox Therapeutics Ltd collaborates with Rett Syndrome Research Trust to evaluate its ExoEdit® exosome-based gene editing platform as a potential therapeutic approach for Rett syndrome. Evox Therapeutics Ltd has announced the launch of a new strategic collaboration with the Rett…
New clinical study results highlight significant reductions in residual stone volume and follow-up health complications with Calyxo’s CVAC System. Calyxo, Inc., a medical device innovator transforming the treatment of kidney stones, has announced the peer-reviewed publication of pivotal clinical data…
Alpha Cognition Enrolls First Patient in BEACON Phase 4 Study Evaluating ZUNVEYL® in Long-Term Care Patients with Alzheimer’s Disease Alpha Cognition Inc. a clinical-stage biopharmaceutical company focused on advancing innovative therapies for neurodegenerative diseases, today announced a significant milestone in…
Supporting Research and Raising Awareness to Fight Prostate Cancer Nationwide During last night’s Atlanta Hawks game, presented by Emory Healthcare, the Atlanta Hawks Foundation, in partnership with the Ressler Gertz Family Foundation, announced a generous $150,000 donation to the Prostate…
Raising Awareness During Kidney Cancer Awareness Month: Uniting Communities for a Common Cause Each March, communities across the United States come together to observe Kidney Cancer Awareness Month, a dedicated time to shine a spotlight on a disease that continues…
Brainlab and Precision NeuroMed Forge Strategic Partnership to Revolutionize AI-Driven Brain Therapy In a major leap forward for neurological care, Brainlab SE (Brainlab), a global leader in digital medical technology, and Precision NeuroMed (PNM), a clinical-stage biotechnology company pioneering precision…
Gilead Sciences Presents Positive Phase 3 ARTISTRY Trial Data for Investigational Bictegravir/Lenacapavir HIV Regimen at CROI 2026 Gilead Sciences, Inc. today shared compelling new data from its Phase 3 ARTISTRY-1 and ARTISTRY-2 clinical trials at the 33rd Conference on Retroviruses…
Backed by the Wyss Center for Bio and Neuroengineering and leading Swiss investors, Clee Medical advances ultra-high-resolution real-time imaging to enhance precision and safety in brain surgery. The Wyss Center for Bio and Neuroengineering in Geneva has announced the successful…
The U.S. Food and Drug Administration sets a PDUFA target date of June 30, 2026, accelerating review of olezarsen for patients with severe hypertriglyceridemia. Ionis Pharmaceuticals, Inc. has announced a major regulatory milestone in its efforts to address severe hypertriglyceridemia…